Sabra Health Care REIT, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-89.5% vs price
Base Case (Median)
-70.1% vs price
Bull Case (75th pct.)
-19.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-10.05 | -149.5% | High (40%) |
| PE Comparable | $3.87 | -81.0% | Medium (25%) |
| Growth Trajectory DCF | $1.56 | -92.3% | Medium (20%) |
| Graham Number | $8.27 | -59.3% | Low (10%) |
| EV/EBITDA | $18.93 | -6.8% | Medium (20%) |
| EV/FCF | $28.71 | 41.4% | Medium (20%) |
Based on 6 out of 8 methods, SBRA appears overvalued at the current price of $20.31. The base case fair value of $6.07 implies 70.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.